Your browser doesn't support javascript.
loading
The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.
Visentin, Andrea; Bonaldi, Laura; Rigolin, Gian Matteo; Mauro, Francesca Romana; Martines, Annalisa; Frezzato, Federica; Pravato, Stefano; Gargarella, Leila Romano; Bardi, Maria Antonella; Cavallari, Maurizio; Volta, Eleonora; Cavazzini, Francesco; Nanni, Mauro; Facco, Monica; Piazza, Francesco; Guarini, Anna; Foà, Robin; Semenzato, Gianpietro; Cuneo, Antonio; Trentin, Livio.
Affiliation
  • Visentin A; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua.
  • Bonaldi L; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padua.
  • Rigolin GM; Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara.
  • Mauro FR; Hematology division, Department of Precision and Translational Medicine, "Sapienza" University, Rome.
  • Martines A; Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS, Padua.
  • Frezzato F; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua.
  • Pravato S; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua.
  • Gargarella LR; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua.
  • Bardi MA; Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara.
  • Cavallari M; Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara.
  • Volta E; Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara.
  • Cavazzini F; Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara.
  • Nanni M; Hematology division, Department of Precision and Translational Medicine, "Sapienza" University, Rome.
  • Facco M; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua.
  • Piazza F; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua.
  • Guarini A; Hematology division, Department of Precision and Translational Medicine, "Sapienza" University, Rome.
  • Foà R; Hematology division, Department of Precision and Translational Medicine, "Sapienza" University, Rome.
  • Semenzato G; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua.
  • Cuneo A; Hematology section, Department of Medical Sciences, Azienda Ospedaliera- Universitaria, Arcispedale S. Anna, University of Ferrara.
  • Trentin L; Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy; Veneto Institute of Molecular Medicine, Padua. livio.trentin@unipd.it.
Haematologica ; 107(4): 868-876, 2022 04 01.
Article in En | MEDLINE | ID: mdl-34092056
ABSTRACT
Complex karyotype (CK) at chronic lymphocytic leukemia (CLL) diagnosis is a negative biomarker of adverse outcome. Since the impact of CK and its subtypes, namely type-2 CK (CK with major structural abnormalities) or high-CK (CK with ≥5 chromosome abnormalities), on the risk of developing Richter syndrome (RS) is unknown, we carried out a multicenter real-life retrospective study to test its prognostic impact. Among 540 CLL patients, 107 harbored a CK at CLL diagnosis, 78 were classified as CK2 and 52 as high-CK. Twenty-eight patients developed RS during a median follow-up of 6.7 years. At the time of CLL diagnosis, CK2 and high-CK were more common and predicted the highest risk of RS transformation, together with advanced Binet stage, unmutated (U)-IGHV, 11q-, and TP53 abnormalities. We integrated these variables into a hierarchical model high-CK and/or CK2 patients showed a 10-year time to RS (TTRS) of 31%; U-IGHV/11q- /TP53 abnormalities/Binet stage B-C patients had a 10-year TTRS of 12%; mutated (M)-IGHV without CK and TP53 disruption a 10-year TTRS of 3% (P<0.0001). We herein demonstrate that CK landscape at CLL diagnosis allows the risk of RS transformation to be refined and we recapitulated clinico-biological variables into a prognostic model.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Lymphoma, Large B-Cell, Diffuse Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Haematologica Year: 2022 Document type: Article Publication country: IT / ITALIA / ITALY / ITÁLIA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Lymphoma, Large B-Cell, Diffuse Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Haematologica Year: 2022 Document type: Article Publication country: IT / ITALIA / ITALY / ITÁLIA